Lower irisin level in patients with type 2 diabetes mellitus: A case‐control study and meta‐analysis

Zhang, Chun; Ding, Zhi; Lv, Guoqiang; Li, Jianping; Zhou, Ping; Zhang, Junfeng

doi:10.1111/1753-0407.12256

Cited by 85 publications

(71 citation statements)

References 16 publications

(56 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Irisin levels on patients with T2DM and additional findings Five studies [6,12,20,21,27] of this review showed reduced levels of irisin on patients with T2DM. Other three researches [22,25,26] did not evidence significant differences between diabetic patients and control groups.…”

Section: Discussionmentioning

confidence: 78%

“…Zhang et al [27] aimed on their study to stablish a confidence interval of the irisin levels on patients with T2DM, using a case-control study and a meta-analysis. In the case-control study, the irisin concentrations were lower on newly-diagnosed diabetic patients when compared to healthy controls.…”

Section: Discussionmentioning

confidence: 99%

“…The analyzed studies on this review made clear the limitations found during their researches, except Zhang et al [27]. A common limitation to all the articles was the reduced size of the samples.…”

Section: Limitations Of the Studiesmentioning

confidence: 91%

“…Three studies (Choi et al [6], Xie et al [22], Tang et al [25]) used the criteria defined by the World Health Organization (WHO) to characterize the cases of diabetes mellitus; other three (Sanchis Gomar et al [26], Wang et al [20], Zhang et al [27] used the American Diabetes Association criteria, and two of them (Kurdiova et al [12], Xiang et al [21]) did not explain the chosen parameters.…”

mentioning

confidence: 99%

“…Seven studies (Choi et al [6], Kurdiova et al [12], Wang et al [20], Xiang et al [21], Xie et al [22], Tang et al [25], Zhang et al [27]) included on its sample only patients newly diagnosed and just Sanchis Gomar et al [26] applied as selection criteria the absence of current treatment like insulin and/ or statins to compose the sample. The main results found on the review are listed on the (Table 2).…”

mentioning

confidence: 99%

See 4 more Smart Citations

Low Irisin Levels in Patients with Type 2 Diabetes Mellitus without Current Treatment: A Systematic Review

Alencar¹,

Luna²,

Coelho³

et al. 2017

int arch med

View full text Add to dashboard Cite

Background: The Irisin is a myokine associated with the improvement on insulin resistance caused by diet and increased physical energy expenditure. Recent studies have shown that patients with Type 2 Diabetes Mellitus (T2DM) have reduced levels of irisin, showing it as a potential marker for various endocrine and cardiovascular diseases. This study aimed to verify if T2DM patients never treated or without ongoing treatment have reduced levels of irisin when compared to individuals with other metabolic profiles. Methods and Findings:Systematic review of the literature, considering the primary studies published in 2012 to 2016, with the outcome Irisin levels in patients never treated or without current treatment in the ambience of Type 2 Diabetes Mellitus. The search was conducted through the electronic database Scopus (Elsevier), using the key words: "Irisin", "Human" and "Diabetes Mellitus". From the 91 studies found, 8 met the eligibility criteria. Significant differences were found on levels of irisin in patients with T2DM compared to normoglycemic individuals, obese and/or pre-diabetic. On average, there was a reduction of 15 pg/ml in plasma levels of irisin in diabetics. However, a minority of studies says that this relationship does not exist. Conclusion:Irisin reduced levels were found in patients with T2DMand is also related to lipid profile, with the risk of developing endocrine diseases, such as diabetes and obesity, and high risk for cardiovascular diseases because of its relationship with endothelial dysfunction. This Low Irisin Levels in Patients with IntroductionDiabetes mellitus is the most common chronic disease characterized by hyperglycemia resulting from defects in insulin secretion and/or activity [1].Its incidence increases gradually each year. The worldwide prevalence of diabetes among adults was 6.4%, affecting 285 million people in 2010, and is expected to increase to 7.7% (ie, 439 million adults) in 2030 [2]. Obesity, especially visceral is one of the most important factors in the development of diabetes through various mechanisms, including increased circulating free fatty acids, secretion of cytokines by white adipose tissue, which ultimately exacerbates insulin resistance, and decreased adiponectin [3], a derived from white adipose tissue cytokine that has been linked to insulin sensitizing activity and cardiovascular protective properties [4]. The brown adipose tissue acts oxidizing chemical energy to produce heat as a defense against hypothermia and obesity [5], may alter insulin sensitivity [6,7,8,9].The reduction in physical activity has also been associated with an increase in the development of chronic diseases, including type 2 diabetes mellitus (T2DM) [10]. One possible explanation for this is the secretion of myokine by the muscular system [11]. Contraction of the skeletal muscle secretes a spectrum of bioactive molecules known as 'myokine', coordinating the flow of energy needed to sustain muscle activity and stimulating the adaptive plasticity of muscle and various ...

show abstract

Section: Discussionmentioning

confidence: 78%

Section: Discussionmentioning

confidence: 99%

Section: Limitations Of the Studiesmentioning

confidence: 91%

mentioning

confidence: 99%

mentioning

confidence: 99%

See 3 more Smart Citations

Low Irisin Levels in Patients with Type 2 Diabetes Mellitus without Current Treatment: A Systematic Review

Alencar¹,

Luna²,

Coelho³

et al. 2017

int arch med

View full text Add to dashboard Cite

show abstract

Irisin attenuates oxidized low‐density lipoprotein impaired angiogenesis through AKT/mTOR/S6K1/Nrf2 pathway

Zhang

Jiang

2019

Journal Cellular Physiology

View full text Add to dashboard Cite

It is known that irisin increases total body energy expenditure, decreases body weight, and enhances insulin sensitivity. Although previous studies have demonstrated that irisin induces vascular endothelial cell (EC) angiogenesis, the molecular mechanisms underlying irisin‐induced angiogenesis under conditions reflecting atherosclerosis are not known. The aim of the present study is to investigate whether irisin could inhibit oxidized low‐density lipoprotein (oxLDL) impaired angiogenesis. We investigated the effect of irisin on angiogenesis in vitro by evaluating cell viability, cell migration, and the capacity to form capillary‐like tubes using human umbilical vein endothelial cells and human microvascular endothelial cells (HUVECs and HMEC‐1) that were treated with oxLDL. We also evaluated the effects of irisin on angiogenesis in vivo by Matrigel plug angiogenesis assay and in a chicken embryo membrane (CAM) model. Our results demonstrated that irisin increased oxLDL‐treated EC viability as well as migration and tube formation. Moreover, oxLDL inhibited angiogenic response in vivo, both in the Matrigel plug angiogenesis assay and in the CAM model, and was attenuated by irisin. Furthermore, irisin decreased apoptosis, inflammatory cytokines, and intracellular reactive oxygen species (ROS) levels in oxLDL‐treated EC. In addition, we found that irisin upregulated pAkt/mTOR/Nrf2 in oxLDL‐treated EC. Both mTOR/Nrf2 shRNA and LY294002 could inhibit the protective effect of irisin. Taken together these results, they suggested that irisin attenuates oxLDL‐induced vascular injury by activating the Akt/mTOR/Nrf2 pathway. Our findings suggest that irisin attenuates oxLDL‐induced blood vessel injury.

show abstract

Muskulatur: „peripheres mechanisch- und Signalstoff-gestütztes Zentrum der Gesundheit“

Laube

2023

Bewegungsmangel

View full text Add to dashboard Cite

Lower irisin level in patients with type 2 diabetes mellitus: A case‐control study and meta‐analysis

Abstract: This study confirmed that circulating irisin concentrations were significantly lower in patients with T2DM.

Cited by 85 publications

References 16 publications

Low Irisin Levels in Patients with Type 2 Diabetes Mellitus without Current Treatment: A Systematic Review

Low Irisin Levels in Patients with Type 2 Diabetes Mellitus without Current Treatment: A Systematic Review

Irisin attenuates oxidized low‐density lipoprotein impaired angiogenesis through AKT/mTOR/S6K1/Nrf2 pathway

Muskulatur: „peripheres mechanisch- und Signalstoff-gestütztes Zentrum der Gesundheit“

Contact Info

Product

Resources

About